Alvotech (OISE:ALVO) Research & Development: kr21,385 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OISE:ALVO Alvotech OISE:ALVO
55 GF Score
Price kr409.00
GF Value kr2,307.75
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Alvotech Research & Development?

Alvotech OISE:ALVO -1.21% 55 Research & Development is kr21,385 Mil as of Mar. 2026. GuruFocus rates OISE:ALVO with a GF Score™ of 55/100 and a GF Value™ of kr2,307.75 (Possible Value Trap). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Alvotech's Research & Development for the three months ended in Mar. 2026 was kr3,074 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was kr21,385 Mil.

Alvotech  (OISE:ALVO) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Alvotech Research & Development Related Terms

Alvotech Research & Development Historical Data

* Premium members only.

The historical data trend for Alvotech's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alvotech Research & Development Chart

Alvotech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 23,951.96 22,649.82 26,437.49 21,482.35 23,097.62

Alvotech Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,786.48 6,861.71 6,472.97 4,976.46 3,073.66
OISE:ALVO
55GF Score
Alvotech OISE:ALVO
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alvotech Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr21,385 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of kr21,385 Mil mean?
Alvotech (OISE:ALVO) has a Research & Development of kr21,385 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Alvotech and its competitors.
Is Alvotech's Research & Development too high?
Alvotech's current Research & Development is kr21,385 Mil. Overall, Alvotech has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Alvotech's Research & Development compare to PAHC and COLL?
Alvotech's Research & Development of kr21,385 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Alvotech and its competitors. Alvotech's current Research & Development is kr21,385 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alvotech stock overvalued right now?
Based on GuruFocus' analysis, Alvotech (OISE:ALVO) is currently considered Possible Value Trap. The stock's GF Value™ is kr2,307.75, compared to a current price of kr409.00 — trading 82.3% below its estimated fair value. The current Research & Development is kr21,385 Mil. Alvotech's overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Alvotech (OISE:ALVO), the current Research & Development is kr21,385 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alvotech (OISE:ALVO) Overvalued in 2026?

Based on GuruFocus' analysis, Alvotech stock appears to be undervalued. The current stock price of kr409.00 is trading 82.3% below its estimated GF Value™ of kr2,307.75. GuruFocus considers Alvotech to be Possible Value Trap.

Key valuation signals for OISE:ALVO:

  • Research & Development: kr21,385 Mil
  • GF Value™: kr2,307.75 vs. price of kr409.00 (82.3% below fair value)
  • GF Score™: 55/100 with 7 warning signs

No single metric tells the full story. See the OISE:ALVO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alvotech Business Description

Other Exchanges ALVO:USAZ45:Germany
Address 9, rue de Bitbourg, Luxembourg, LUX, L-1273
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
55GF Score

Get the complete analysis for OISE:ALVO

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr409.00
Price
kr2,307.75
GF Value